11 Nov '21
DALLAS, Texas , Nov. 11, 2021 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (“Vaxxinity”), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced the pricing of its initial public offering of 6,000,000 shares of class A common stock at a public offering price
01 Apr '21
New U.S. corporation consolidates chronic and infectious disease vaccines and immunotherapeutics to democratize health on a global scale DALLAS, TX  (April 1, 2021)  – COVAXX and United Neuroscience today announced the consolidation of their vaccine development efforts under the newly formed